Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolisation in Unresectable Hepatocellular Carcinoma (EMERALD-Y90): Interim Safety Analysis with Contextualisation Using an External Comparator Arm
Cancers · 10.11.2026 · 18 (22) · 3598
DOI: 10.3390/cancers18223598 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 10.11.2026. Verfasst von Renuka Iyer und 13 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.
Abstract (Originalsprache)
Background/Objectives: EMERALD-Y90 (NCT06040099) is a phase II, open-label, single-arm study evaluating Y90 transarterial radioembolisation (TARE) plus durvalumab and bevacizumab for unresectable hepatocellular carcinoma (uHCC) amenable to TARE, without extrahepatic spread. Interim safety was compared with an EMERALD-1 external comparator arm (ECA).
Methods
Participants received TARE with dosimetry, durvalumab (1500 mg) ≥ 14 days later, then durvalumab (1120 mg) plus bevacizumab (15 mg/kg) every 21 days from ≥ 14 days later. Safety was assessed across treatment intervals. The ECA included EMERALD-1 participants who received transarterial chemoembolisation, durvalumab and bevacizumab, and met EMERALD-Y90 eligibility. Inverse probability of treatment weighting balanced prespecified baseline characteristics before comparisons.
Results
At the 9 January 2026 cut-off, 59 participants received TARE (safety set), 58 received durvalumab and 57 received bevacizumab. Treatment-emergent adverse events (TEAEs) occurred in 58 (98.3%) participants, including Grade 3/4 TEAEs in 30 (50.8%); 53 (89.8%) had treatment-related adverse events (TRAEs); 18 (30.5%) had serious adverse events and 8 died (6 unrelated to treatment). Common TEAEs were gastrointestinal (89.8%), musculoskeletal (54.2%), respiratory (54.2%), skin-related (52.5%), and nervous system-related (50.8%). After weighting, EMERALD-Y90 (N = 58) and EMERALD-1 ECA (N = 45) had balanced baseline characteristics and descriptively similar safety; TRAEs occurred in 52 (86.5%) and 40 (87.5%) participants, respectively.
Conclusions
In this interim safety analysis of EMERALD-Y90, TARE followed by durvalumab and bevacizumab showed an encouraging safety profile, consistent with the known component profiles, without new safety signals versus these profiles. Observed safety was broadly similar to the EMERALD-1 ECA, supporting further investigation of this approach in embolisation-eligible uHCC.
Förderung
- AstraZeneca
Zitieren
APA
Iyer, R., Kulik, L., Spieler, B., Noonan, A., White, S. B., Lewandowski, R. J., Malone, C., Lindquist, J., Zakari, A., Richa, D. C., Schmidt, J. C. F., Gogna, P., Underwood, D., & Salem, R. (2026). Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolisation in Unresectable Hepatocellular Carcinoma (EMERALD-Y90): Interim Safety Analysis with Contextualisation Using an External Comparator Arm. Cancers, 18(22), 3598. https://doi.org/10.3390/cancers18223598
Vancouver
Iyer R, Kulik L, Spieler B, Noonan A, White SB, Lewandowski RJ, et al. Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolisation in Unresectable Hepatocellular Carcinoma (EMERALD-Y90): Interim Safety Analysis with Contextualisation Using an External Comparator Arm. Cancers. 2026;18(22):3598. doi:10.3390/cancers18223598
BibTeX
@article{Iyer2026,
author = {Iyer, Renuka and Kulik, Laura and Spieler, Benjamin and Noonan, Anne and White, Sarah B. and Lewandowski, Robert J. and Malone, Christopher and Lindquist, Jonathan and Zakari, Ahmed and Richa, D. Chimene and Schmidt, James C. F. and Gogna, Priyanka and Underwood, Dex and Salem, Riad},
title = {Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolisation in Unresectable Hepatocellular Carcinoma (EMERALD-Y90): Interim Safety Analysis with Contextualisation Using an External Comparator Arm},
journal = {Cancers},
year = {2026},
volume = {18},
number = {22},
pages = {3598},
doi = {10.3390/cancers18223598}
}
EUVIMED